KR20180123586A - 피리미딘 유도체의 제조 방법 - Google Patents

피리미딘 유도체의 제조 방법 Download PDF

Info

Publication number
KR20180123586A
KR20180123586A KR1020187032263A KR20187032263A KR20180123586A KR 20180123586 A KR20180123586 A KR 20180123586A KR 1020187032263 A KR1020187032263 A KR 1020187032263A KR 20187032263 A KR20187032263 A KR 20187032263A KR 20180123586 A KR20180123586 A KR 20180123586A
Authority
KR
South Korea
Prior art keywords
compound
formula
substituted
group
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187032263A
Other languages
English (en)
Korean (ko)
Inventor
존 빈센트 칼리에니
마릴린 데 라 크루즈
디트마 플루바하
바오칭 공
프라사드 코테스와라 카파
피오트르 에이치. 카르핀스키
후이 리우
파스칼 미셀
라스무스 모스
마리아 카트리나 테스타
릴라드하르 멀리드하르 웨이콜
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44773179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180123586(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20180123586A publication Critical patent/KR20180123586A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
KR1020187032263A 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법 Ceased KR20180123586A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38872110P 2010-10-01 2010-10-01
US61/388,721 2010-10-01
US201161494915P 2011-06-09 2011-06-09
US61/494,915 2011-06-09
PCT/US2011/053808 WO2012044727A2 (en) 2010-10-01 2011-09-29 Manufacturing process for pyrimidine derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137011172A Division KR20130119928A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법

Publications (1)

Publication Number Publication Date
KR20180123586A true KR20180123586A (ko) 2018-11-16

Family

ID=44773179

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187032263A Ceased KR20180123586A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법
KR1020137011172A Ceased KR20130119928A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137011172A Ceased KR20130119928A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법

Country Status (30)

Country Link
US (3) US9181215B2 (https=)
EP (2) EP2621908A2 (https=)
JP (3) JP5998145B2 (https=)
KR (2) KR20180123586A (https=)
CN (3) CN103140479B (https=)
AR (1) AR083213A1 (https=)
AU (4) AU2011308856B2 (https=)
BR (1) BR112013007123B1 (https=)
CA (1) CA2813333C (https=)
CL (2) CL2013000850A1 (https=)
CO (1) CO6700837A2 (https=)
DK (1) DK3040333T3 (https=)
EC (1) ECSP13012596A (https=)
ES (1) ES2699951T3 (https=)
GT (1) GT201300080A (https=)
HU (1) HUE041326T2 (https=)
IL (3) IL225113A (https=)
LT (1) LT3040333T (https=)
MX (1) MX354482B (https=)
MY (1) MY160785A (https=)
NZ (1) NZ608285A (https=)
PE (1) PE20140002A1 (https=)
PH (2) PH12013500579A1 (https=)
PL (1) PL3040333T3 (https=)
PT (1) PT3040333T (https=)
RU (2) RU2576619C2 (https=)
SG (1) SG188439A1 (https=)
SI (1) SI3040333T1 (https=)
TW (1) TWI540133B (https=)
WO (1) WO2012044727A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635189B (zh) 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
PL2912030T3 (pl) * 2012-10-23 2017-02-28 Novartis Ag Ulepszony sposób wytwarzania 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4- trifluorometylopirydyno-2-aminy
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9318944B2 (en) 2013-04-29 2016-04-19 Rockwell Automation Technologies, Inc. Methods and apparatus for active front end filter capacitor degradation detection
US9294005B2 (en) 2013-10-01 2016-03-22 Rockwell Automation Technologies, Inc. Method and apparatus for detecting AFE filter capacitor degradation
NZ718487A (en) * 2013-10-16 2020-01-31 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
RU2688665C2 (ru) * 2014-04-22 2019-05-22 Университет Базель Новый способ получения производных триазина, пиримидина и пиридина
CN105085476B (zh) * 2014-11-24 2018-03-09 苏州晶云药物科技有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
AU2015366357B2 (en) * 2014-12-17 2018-07-19 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
US9481665B2 (en) * 2015-03-13 2016-11-01 Yong Xu Process for preparing PI3K inhibitor buparsilib
EP3273959A1 (en) 2015-03-25 2018-01-31 Novartis Ag Pharmaceutical combinations
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
CN106543140A (zh) * 2015-09-21 2017-03-29 苏州晶云药物科技有限公司 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
PL3978500T3 (pl) * 2015-12-16 2024-03-11 Genentech, Inc. Sposób wytwarzania tricyklicznych związków inhibitorów pi3k
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN107793394A (zh) * 2017-08-03 2018-03-13 上海厚璞生物科技有限公司 一种生产选择性pi3k抑制剂的系列关键中间体
CN110016142B (zh) * 2019-04-30 2021-08-03 合肥工业大学 一种含嘧啶硼酸结构的硅油及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124476A (en) 1998-04-17 2000-09-26 Symyx Technologies, Inc. Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates
CN1735598A (zh) * 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2008098058A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
CN102958518A (zh) * 2009-05-15 2013-03-06 诺瓦提斯公司 磷脂酰肌醇3-激酶抑制剂和抗糖尿病化合物的组合

Also Published As

Publication number Publication date
US9452994B2 (en) 2016-09-27
JP2016128414A (ja) 2016-07-14
US9359326B2 (en) 2016-06-07
JP2013541536A (ja) 2013-11-14
RU2576619C2 (ru) 2016-03-10
CL2013000850A1 (es) 2013-09-27
TW201215605A (en) 2012-04-16
US20130225571A1 (en) 2013-08-29
JP5998145B2 (ja) 2016-09-28
EP3040333A1 (en) 2016-07-06
AU2015246141B2 (en) 2016-07-07
IL238046A (en) 2016-08-31
ES2699951T3 (es) 2019-02-13
AU2015200938A1 (en) 2015-03-12
LT3040333T (lt) 2018-12-10
AR083213A1 (es) 2013-02-06
IL233282A0 (en) 2014-08-31
WO2012044727A2 (en) 2012-04-05
BR112013007123B1 (pt) 2021-11-09
SG188439A1 (en) 2013-05-31
ECSP13012596A (es) 2013-07-31
IL225113A (en) 2016-08-31
HUE041326T2 (hu) 2019-05-28
KR20130119928A (ko) 2013-11-01
CA2813333A1 (en) 2012-04-05
US20150232446A1 (en) 2015-08-20
BR112013007123A2 (pt) 2016-06-14
SI3040333T1 (sl) 2019-01-31
IL233282A (en) 2016-08-31
AU2015200936A1 (en) 2015-03-12
PH12013500579A1 (en) 2016-06-10
AU2015246141A1 (en) 2015-11-12
PL3040333T3 (pl) 2019-03-29
AU2011308856A1 (en) 2013-03-28
EP2621908A2 (en) 2013-08-07
US20160251334A1 (en) 2016-09-01
CN103140479B (zh) 2015-04-08
RU2015150728A (ru) 2019-01-15
CN103140479A (zh) 2013-06-05
GT201300080A (es) 2014-07-18
MX354482B (es) 2018-03-07
US9181215B2 (en) 2015-11-10
EP3040333B1 (en) 2018-09-12
MX2013003507A (es) 2013-05-20
DK3040333T3 (da) 2019-01-02
MY160785A (en) 2017-03-15
CL2015001088A1 (es) 2015-07-10
JP2016106091A (ja) 2016-06-16
CA2813333C (en) 2019-01-15
WO2012044727A3 (en) 2012-06-07
HK1220686A1 (en) 2017-05-12
AU2015200938B2 (en) 2015-11-19
CN104987321A (zh) 2015-10-21
CN104945373A (zh) 2015-09-30
AU2011308856B2 (en) 2015-04-23
RU2013120326A (ru) 2014-11-20
CO6700837A2 (es) 2013-06-28
NZ608285A (en) 2014-06-27
PT3040333T (pt) 2018-12-04
PH12015501585A1 (en) 2015-09-21
PE20140002A1 (es) 2014-01-21
TWI540133B (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
KR20180123586A (ko) 피리미딘 유도체의 제조 방법
CA2759241C (en) Novel anti-inflammatory agents
CA2901022C (en) Substituted pyridine compounds as inhibitors of histone demethylases
PT2316831E (pt) 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
CN105722840B (zh) 作为PI3K、mTOR抑制剂的稠合喹啉化合物
AU2012214413A1 (en) Method of inhibiting hamartoma tumor cells
JP2025532626A (ja) 複素環式ｓｉｋ阻害薬
HK40119202A (zh) 杂环类sik抑制剂
CN112062717A (zh) 一种吲哚胺2,3-双加氧酶抑制剂
OA17463A (en) Inhibitors of histone demethylases.
HK1197888B (en) Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181107

Application number text: 1020137011172

Filing date: 20130430

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181206

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181212

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181212

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I